The Board of Probi evaluates the mandatory public cash offer from Symrise

Symrise AG (”Symrise”) has today 6 February 2014 announced a mandatory public
cash offer to the shareholders in Probi to transfer all of their shares in Probi
to Symrise for a price of SEK 40,10 in cash for each share in Probi (the
”Mandatory Offer”). Symrise has declared that it holds approximately 30.03 per
cent of the capital and votes in Probi and states that the Mandatory Offer is
launched in accordance with the special provisions regarding mandatory bids in
the Stock Market Takeover Bids Act (2006:451).

Symrise has stated that an offer document is expected to be made public around
11 February 2014 and in connection therewith be distributed to the shareholders
in Probi. Symrise has further stated that the acceptance period for the
Mandatory Offer is expected to end around 12 March 2014.

The Board will announce its opinion of the Mandatory Offer and the reasons for
its opinion, as well as an opinion from independent expertise as to the fairness
of the Mandatory Offer consideration. The opinion of the Board and the fairness
opinion are expected to be made public on 10 February 2014 and can thereby be
included in Symrise’s offer document to the shareholders in Probi.

Declan MacFadden, board member of Probi, is President of Symrise Asia Pacific,
Flavor & Nutrition business based in Singapore. Due to conflict of interest, he
will not participate in the Board’s processing of or resolutions concerning the
Mandatory Offer. Based on information from Symrise, Declan MacFadden is
considered to participate in the Mandatory Offer. On this basis, the Company has
an obligation in accordance with section III, paragraph 3 in the takeover rules
issued by NASDAQ OMX Stockholm to obtain and make public a fairness opinion from
independent expertise. The Board has retained Erik Penser Bankaktiebolag to
issue a fairness opinion concerning the Mandatory Offer.

Lund on 6 February 2014
Probi AB (publ)
The Board

This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act.

This is a translation of the Swedish version of the press release. In case of
discrepancies, the Swedish wording prevails.

FOR MORE INFORMATION, PLEASE CONTACT:
Per Lundin, Chairman of the Board, Probi, mobile +46 705 74 11 71, e-mail:
per.lundin@transit.se

ABOUT PROBI
Probi is a leading player in probiotic research and the development of efficient
and well-documented probiotics. Its research areas include: gastrointestinal
tracts, immune system, metabolic syndrome and stress and recovery. Probi’s
customers are leading companies in the Functional Food and Consumer Healthcare
segments. Total income for 2013 totalled MSEK 103,6. Probi’s share is listed on
the NASDAQ OMX Stockholm, Small Cap. Probi has approximately 4,000 shareholders.
Read more at www.probi.se.